ATE404574T1 - Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden - Google Patents

Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Info

Publication number
ATE404574T1
ATE404574T1 AT04809566T AT04809566T ATE404574T1 AT E404574 T1 ATE404574 T1 AT E404574T1 AT 04809566 T AT04809566 T AT 04809566T AT 04809566 T AT04809566 T AT 04809566T AT E404574 T1 ATE404574 T1 AT E404574T1
Authority
AT
Austria
Prior art keywords
proliferation
inhibiting
platinum complexes
tumor cells
complexes
Prior art date
Application number
AT04809566T
Other languages
English (en)
Inventor
James Turkson
Richard Jove
Jay Palmer
Heidi Kay
Hua Yu
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE404574T1 publication Critical patent/ATE404574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04809566T 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden ATE404574T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48122603P 2003-08-13 2003-08-13
US51558003P 2003-10-30 2003-10-30
US51994303P 2003-11-14 2003-11-14
US52529503P 2003-11-25 2003-11-25

Publications (1)

Publication Number Publication Date
ATE404574T1 true ATE404574T1 (de) 2008-08-15

Family

ID=34199238

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04781131T ATE453653T1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren
AT04809566T ATE404574T1 (de) 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04781131T ATE453653T1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren

Country Status (8)

Country Link
US (6) US7238372B2 (de)
EP (2) EP1664070B1 (de)
JP (2) JP2007502777A (de)
AT (2) ATE453653T1 (de)
AU (3) AU2004270655B2 (de)
CA (2) CA2535584A1 (de)
DE (2) DE602004024909D1 (de)
WO (2) WO2005023824A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE453653T1 (de) 2003-08-13 2010-01-15 Univ South Florida Platinkomplexe zur behandlung von tumoren
US20050288365A1 (en) 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
WO2005110477A2 (en) * 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
WO2007008247A2 (en) 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
US7951374B2 (en) 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
DE102004060934A1 (de) * 2004-12-17 2006-06-29 Wacker Chemie Ag Vernetzbare Polyorganosiloxanmassen
AU2006266446B2 (en) * 2005-06-30 2011-03-10 Bionumerik Pharmaceuticals, Inc. Monoazole ligand platinum analogs
US20100190180A1 (en) * 2005-07-06 2010-07-29 Heidi Kay Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
WO2007047623A2 (en) * 2005-10-14 2007-04-26 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
WO2008144616A1 (en) 2007-05-18 2008-11-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
US8895610B1 (en) 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
CN101778857A (zh) * 2007-06-18 2010-07-14 普拉托技术（私有）公司 铂(iv)络合物
EP3067054B1 (de) * 2007-09-10 2020-12-30 Boston Biomedical, Inc. Neue zusammensetzungen und verfahren für die bekämpfung von krebs
US20100184854A1 (en) * 2008-12-12 2010-07-22 Platco Technologies (Proprietary) Limited Platinum (iv) complexes and methods of use thereof
DK2582847T3 (en) 2010-06-18 2016-12-19 Myriad Genetics Inc METHODS AND MATERIALS TO ASSESS loss of heterozygosity
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
EP4563709A3 (de) 2011-06-17 2025-09-03 Myriad Genetics, Inc. Methoden und materialien zur beurteilung des allelischen ungleichgewichts
RU2491936C2 (ru) * 2011-07-11 2013-09-10 Борис Николаевич Анисимов Способ комплексного лечения больных паразитарными заболеваниями
EP2794907B2 (de) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Verfahren und materialien zur bewertung des verlusts der heterozygotie
CA2864481C (en) 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
BR112015023568B8 (pt) 2013-03-15 2024-01-02 Ann Mcfarland Sherri Composto à base de metal como composto fotodinâmico
EP3693475A1 (de) 2013-04-05 2020-08-12 Myriad Genetics, Inc. Methoden und materialien zur beurteilung eines homologen rekombinationsfehlers
WO2014198140A1 (zh) * 2013-06-13 2014-12-18 上海医药工业研究院 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
US20160185808A1 (en) * 2013-07-25 2016-06-30 Srinivas Ganta Platinum derivatives for hydrophobic formulations
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6877334B2 (ja) 2014-08-15 2021-05-26 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3082295A1 (en) 2017-11-21 2019-05-31 Medoncare Pharmaceutical Co., Ltd Combination products containing dicycloplatin, preparation and use thereof
CN112175014B (zh) * 2020-10-10 2021-08-20 中国药科大学 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (de) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen
WO2024063828A1 (en) 2022-09-21 2024-03-28 Oracle International Corporation Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
GB1432563A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GR851932B (de) * 1984-08-14 1985-12-13 Engelhard Corp
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
JPH01156989A (ja) * 1987-09-25 1989-06-20 Ss Pharmaceut Co Ltd 新規白金錯体
DE68918878T2 (de) * 1988-02-02 1995-02-23 Johnson Matthey Inc Pt(IV) Komplexe.
JP3520367B2 (ja) * 1994-12-22 2004-04-19 独立行政法人産業技術総合研究所 白金ニトロアンミン系錯体の製造方法
EP0812852B1 (de) 1995-02-28 2003-04-23 Yoshinori Kidani Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US5977393A (en) 1997-11-21 1999-11-02 California Institute Of Technology Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
AU758903B2 (en) 1998-11-26 2003-04-03 Pentapharm Ag Transport system conjugate
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7034109B2 (en) 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005002508A2 (en) * 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
ATE453653T1 (de) 2003-08-13 2010-01-15 Univ South Florida Platinkomplexe zur behandlung von tumoren
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
WO2007008247A2 (en) 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
US20100190180A1 (en) 2005-07-06 2010-07-29 Heidi Kay Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression

Also Published As

Publication number Publication date
US8598230B2 (en) 2013-12-03
EP1675864B1 (de) 2009-12-30
JP2007502301A (ja) 2007-02-08
US7763585B2 (en) 2010-07-27
WO2005016946A3 (en) 2005-09-29
US20050074502A1 (en) 2005-04-07
AU2011202386A1 (en) 2011-06-09
WO2005023824A3 (en) 2005-06-09
US8247445B2 (en) 2012-08-21
WO2005016946A2 (en) 2005-02-24
AU2004264421B2 (en) 2011-02-24
AU2004264421A1 (en) 2005-02-24
US20080187992A1 (en) 2008-08-07
US20100310645A1 (en) 2010-12-09
ATE453653T1 (de) 2010-01-15
CA2535762A1 (en) 2005-03-17
JP2007502777A (ja) 2007-02-15
EP1675864A2 (de) 2006-07-05
WO2005023824A2 (en) 2005-03-17
AU2004270655A1 (en) 2005-03-17
US20090285884A1 (en) 2009-11-19
AU2004270655B2 (en) 2011-03-24
US7238372B2 (en) 2007-07-03
CA2535584A1 (en) 2005-02-24
US20100316704A1 (en) 2010-12-16
EP1664070B1 (de) 2008-08-13
US7759510B2 (en) 2010-07-20
US20050080131A1 (en) 2005-04-14
DE602004024909D1 (de) 2010-02-11
EP1664070A2 (de) 2006-06-07
DE602004015811D1 (de) 2008-09-25
US7566798B2 (en) 2009-07-28

Similar Documents

Publication Publication Date Title
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE447965T1 (de) Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE554087T1 (de) Neue kinaseinhibitoren
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
DE69914085D1 (de) Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
DK1866433T3 (da) Fremgangsmåde til identifikation af LRRK-2interagerende molekyler og til rensning af LRRK2
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
DK1773420T3 (da) Anvendelse af gingivale fibroblaster til vaskulær celleterapi
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
TW200716132A (en) Novel chemical compounds
MXPA05001690A (es) Estrategia de deteccion para farmacos anticancer.
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2005086909A3 (en) Protein kinase c iota
WO2006091965A3 (en) Nod1 as an anti-tumor agent
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties